...put its XPO1 inhibitor Xpovio to
the test against the novel coronavirus. In a press release, the company said
the drug has already seen positive preclinical activity against several other
respiratory viruses. For the treatment of relapsed or refractory multiple
myeloma, Xpovio holds preferred status for just 2% of covered lives, growing to
7% with prior authorization and/or step therapy. Xpovio is not covered or not
listed for 21% of insured lives.
SOURCE: MMIT Analytics, as
of 4/8/20
No comments:
Post a Comment